Dobran v. Franciscan Medical Center

777 N.E.2d 907, 149 Ohio App. 3d 455
CourtOhio Court of Appeals
DecidedOctober 4, 2002
DocketC.A. Case No. 19218, T.C. Case No. 99-4687.
StatusPublished
Cited by1 cases

This text of 777 N.E.2d 907 (Dobran v. Franciscan Medical Center) is published on Counsel Stack Legal Research, covering Ohio Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dobran v. Franciscan Medical Center, 777 N.E.2d 907, 149 Ohio App. 3d 455 (Ohio Ct. App. 2002).

Opinion

Grady, Judge.

{¶ 1} This is an appeal from a summary judgment in favor of several defendants on the plaintiffs’ claims for negligent infliction of emotional distress arising from the destruction of a tissue specimen intended to be used in cancer screening. The facts of the case were set out by the trial court in its summary judgment decision:

{¶ 2} “In the beginning of 1998, Plaintiff John Dobran (hereinafter ‘Mr. Dobran’) discovered a mole on his left forearm. On February 11, 1998, Mr. Dobran had his family physician, Dr. Randall, examine this mole. On April 8, *457 1998, Dr. Randall examined the mole once again and found that the mole had a necrotic center, was crusty, and had begun to bleed. The lesion was excised by Dr. Randall on April 20, 1998, and a biopsy was performed. The biopsy showed that the mole was a malignant melanoma. Doctors have found that lesions, particularly those found in the extremities, will drain through the lymphatic system to the lymph nodes. After the biopsy, Mr. Dobran consulted with Dr. Merl, an oncologist, and Dr. Johnson, a plastic surgeon. Dr. Johnson suggested to Mr. Dobran a procedure known as an elective lymph node resection. This procedure involved Dr. Johnson making a wide excision around the initial lesion, and then performing a skin graft. Dr. Johnson also mentioned removing the lymph nodes from under the arm. Mr. Dobran, however, expressed an interest in a sentinel lymph node biopsy. Dr. Johnson then referred Mr. Dobran to Dr. Finley, in order to discuss the sentinel lymph node biopsy procedure and its effectiveness.

{¶ 3} “Mr. Dobran met with Dr. Finley on April 27, 1998. Dr. Finley explained the procedure involved in performing a sentinel lymph node biopsy to Mr. Dobran. The sentinel lymph nodes are the first lymph nodes in the body to be encountered by metastasis of melanoma. These nodes can be harvested in order for doctors to test and determine the prospects of metastasis of the melanoma. A Sentinel lymph node biopsy is a surgical procedure that involves the injection of a radio nucleotide and a dye at the site of the melanoma excision. The sentinel lymph nodes are identified by the migration of the radio nucleotide and dye. The nodes are then removed. Dr. Finley explained that a portion of the sentinel lymph node, once removed, would be tested in Dayton with normal histology (under a microscope) while the other portion would be sent to California for Polymerace Chain Reaction (hereinafter ‘PCR’) screening. After this consultation, Mr. Dobran felt comfortable with the procedure and made the decision to have the sentinel lymph node biopsy performed.

{¶ 4} “The PCR screening, performed in California, is offered by the Sunbelt Melanoma Trial. The trial also offers treatment based upon a protocol. This Trial is a clinical study that evaluates the effectiveness of interferon Alfa-2b, a drug for patients that have melanoma that has spread (metastasized) to the regional lymph nodes. This study also investigates the values of lymphatic mapping and sentinel lymph node biopsies performed to detect early lymph node metastasises. Dr. Finley explained the Trial’s research protocol to Mr. Dobran. Mr. Dobran then signed a consent form to participate in the Sunbelt Melanoma Trial and states in his deposition that he felt he had ‘a clear understanding’ of what to expect of the Trial and of the consent document. Dobran Depo. pgs. 69, 82. The Defendants assert that Mr. Dobran was aware that the Trial involved research and that he could have been terminated from the Trial at any time. Mr. *458 Dobran contends that he was entitled to the PCR screening without any risk of termination according to the consent form that he signed. Mr. Dobran testified that he may not have had the same opportunities for testing and treatment without participating in the Sunbelt Melanoma Trial. Id., at pg. 71.

{¶ 5} “Mr. Dobran had the sentinel lymph node dissection performed on May 1, 1998, at the Franciscan Medical Center. Mr. Dobran does not have any complaints about how this surgery was performed. As explained to Mr. Dobran, one half of Mr. Dobran’s sentinel lymph node underwent traditional histologic testing which produced negative results. The other half of Mr. Dobran’s sentinel lymph node was frozen and mailed to the National Genetics Institute (hereinafter ‘NGI’) in California for PCR screening. When the package arrived at the NGI, the sample was thawed and was not usable for PCR screening or other testing. Mr. Dobran states in his testimony that he feels that he may never know if his cancer has metastasized or not without the PCR screening.

{¶ 6} “In 1999, Mr. Dobran had a second mole removed from his back, and is having the moles systematically removed by his dermatologist. The Defendants in this matter assert that Mr. Dobran does not have any surgeries, chemotherapy, or radiation planned, and Mr. Dobran’s doctors have not recommended that he have surgery to remove additional lymph nodes.

{¶ 7} “Mr. Dobran has brought forth the following claims against the Defendants in regarding this case: 1) Breach of a Bailment Contract; 2) Negligence; and 3) Breach of Fiduciary Duties. Mr. Dobran states in his deposition that he no longer enjoys doing things that he liked to do in the past, including golf and traveling. Mr. Dobran states that he is bothered by the chance that the cancer could return, and states that he would feel better if he knew the percentage of survival. Mr. Dobran testified that the reason that this matter has come before the court is because he does not have results from the PCR screening.” (Decision, at 2-4.)

{¶ 8} The defendants in this action include numerous persons and organizations who were involved in harvesting, shipping, and potentially testing the specimen that was destroyed. Most deny any culpability in its destruction and/or breach of any duty to prevent it. The trial court did not reach those issues, however. Rather, the court granted summary judgment for the defendants on all of the plaintiffs’ claims for relief on a finding that, absent evidence of the presence of metastatic cancer, plaintiff cannot demonstrate that as a result of the negligence alleged he faced an actual physical peril, which the law requires to prove causation on a claim of negligent infliction of emotional distress. Plaintiffs filed a timely notice of appeal.

*459 ASSIGNMENT OF ERROR

{¶ 9} “The trial court erred in granting summary judgment for the defendants.”

{¶ 10} Summary judgment may not be granted unless the entire record demonstrates that there is no genuine issue of material fact and that the moving party is, on that record, entitled to judgment as a matter of law. Civ.R. 56. The burden of showing that no genuine issue of material fact exists is on the moving party. Harless v. Willis Day Warehousing Co. (1978), 54 Ohio St.2d 64, 8 O.O.3d 73, 375 N.E.2d 46. All evidence submitted in connection with a motion for summary judgment must be construed most strongly in favor of the party against whom the motion is made. Morris v. First Natl. Bank & Trust Co. (1970), 21 Ohio St.2d 25, 50 O.O.2d 47, 254 N.E.2d 683.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Innovative Technologies Corp. v. Advanced Mgt. Technology, Inc.
2011 Ohio 5544 (Ohio Court of Appeals, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
777 N.E.2d 907, 149 Ohio App. 3d 455, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dobran-v-franciscan-medical-center-ohioctapp-2002.